| Allos Therapeutics to Present at the 8th Annual Needham Life Sciences Conference |
| WESTMINSTER, Colo., Jun 03, 2009 (BUSINESS WIRE) -- Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company
focused on developing and commercializing innovative small molecule
drugs for the treatment of cancer, today announced that members of the
Company's senior management will present on Wednesday, June 10, at 1:00
p.m. Eastern Time at the 8th Annual Needham Life Sciences Conference
taking place at the New York Palace Hotel.
There will be a live webcast of the presentation, which will be accessible through a link posted on the home page and investor relations section of the Allos website. The webcast will be available for replay through June 26, 2009. About Allos Therapeutics, Inc. Allos Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer. The Company's product candidate, pralatrexate, is a targeted antifolate designed to accumulate preferentially in cancer cells. In March 2009, the Company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval to market pralatrexate for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. In May 2009, the FDA accepted the Company's NDA for priority review and established a Prescription Drug User Fee Act date of September 24, 2009 for a decision regarding approval of the NDA. In addition, pralatrexate is being evaluated in patients with non-small cell lung cancer, bladder cancer and a range of lymphoma sub-types. Allos currently retains exclusive worldwide rights to pralatrexate for all indications. For more information about Allos, visit www.allos.com. Safe Harbor Statement The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Additional information concerning these forward-looking statements and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2009 and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in the presentation. All forward-looking statements are based on information currently available to the Company on the date thereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this presentation, except as required by law.
SOURCE: Allos Therapeutics
Allos Therapeutics |
|